Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. (NCT05201066)
An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
🩺 Plain-English Summary (8th-Grade Level)
This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.
Who can join: Review the eligibility criteria below.
Location: Oregon Health Sciences University — Portland, Oregon
Age range: 12 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Oregon Health Sciences University — Portland, Oregon
- Huntsman Cancer Institute Univ of Utah — Salt Lake City, Utah
- Novartis Investigative Site — Clayton, Victoria
- Novartis Investigative Site — Florianópolis, Santa Catarina
- Novartis Investigative Site — Vancouver, British Columbia
- Novartis Investigative Site — Changchun, Jilin
- Novartis Investigative Site — Tianjin,
- Novartis Investigative Site — Prague,
- Novartis Investigative Site — Toulouse,
- Novartis Investigative Site — Freiburg im Breisgau, Baden-Wurttemberg
- Novartis Investigative Site — Alexandroupoli,
- Novartis Investigative Site — Pátrai,
- Novartis Investigative Site — Brescia, BS
- Novartis Investigative Site — Florence, FI
- Novartis Investigative Site — Genova, GE
- Novartis Investigative Site — Milan, MI
- Novartis Investigative Site — Roma, RM
- Novartis Investigative Site — Fukushima,
- Novartis Investigative Site — Kuala Lumpur,
- Novartis Investigative Site — Badalona, Barcelona
- Novartis Investigative Site — Barcelona,
- Novartis Investigative Site — Madrid,
- Novartis Investigative Site — Zurich,
- Novartis Investigative Site — Izmir,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndromes
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Lakewood, California
- Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida
Explore by condition: All Myelodysplastic Syndromes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.